guest ::
| Home > In process > Development and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders. > print |
| Home > In process > Development and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders. > print |
| 001 | 285634 | ||
| 005 | 20260313131410.0 | ||
| 024 | 7 | _ | |a 10.1007/s00415-026-13740-1 |2 doi |
| 024 | 7 | _ | |a pmid:41805906 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12975812 |2 pmc |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00273 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Vogel, Adam P |0 P:(DE-2719)9000329 |b 0 |
| 245 | _ | _ | |a Development and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders. |
| 260 | _ | _ | |a [Darmstadt] |c 2026 |b Steinkopff |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1773403877_16829 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Impaired speech due to dysarthria significantly impacts quality of life. Patient-reported outcomes (PROs) offer critical insight into the lived experience of communication disability and are central to regulatory frameworks for patient-focused drug development.To develop and validate the Dysarthria Impact Scale (DIS), a brief PRO designed to assess the impact of motor speech disorders on quality of life across neurological conditions.A multi-site, cross-sectional study was conducted with 244 participants, including individuals with Huntington's disease, Parkinson's disease, hereditary ataxias, and head and neck cancer, and healthy controls. The 22-item DIS was developed using expert input and patient feedback and evaluated alongside reference tools (Voice Handicap Index and SF-36). Item reduction procedures yielded two shorter versions (DIS-17 and DIS-6). Validity, reliability, and sensitivity/specificity analyses were performed, and minimal clinically important differences (MCIDs) were estimated using distribution-based methods.All DIS versions showed strong convergent validity with the VHI (r = -0.85) and SF-36 (r = 0.72) and were correlated with blinded perceptual speech ratings. DIS-17 and DIS-6 achieved comparable sensitivity (0.93 and 0.88) and specificity (0.84 and 0.86, respectively). Test-retest reliability was high (r = 0.98), with estimated MCIDs and within-subject variability provided. Group differences were observed, with lower DIS scores in ataxia and Parkinson's disease compared to Huntington's disease.The DIS is a valid, reliable, and practical PRO for quantifying the impact of dysarthria on quality of life. Longitudinal responsiveness remains to be established. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Clinical trials |2 Other |
| 650 | _ | 7 | |a Dysarthria |2 Other |
| 650 | _ | 7 | |a Patient-reported outcome |2 Other |
| 650 | _ | 7 | |a Questionnaire |2 Other |
| 650 | _ | 7 | |a Speech |2 Other |
| 650 | _ | 7 | |a Survey |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Dysarthria: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Dysarthria: etiology |2 MeSH |
| 650 | _ | 2 | |a Dysarthria: psychology |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Patient Reported Outcome Measures |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Reproducibility of Results |2 MeSH |
| 650 | _ | 2 | |a Quality of Life |2 MeSH |
| 650 | _ | 2 | |a Severity of Illness Index |2 MeSH |
| 700 | 1 | _ | |a Graf, Lisa |0 P:(DE-2719)9001369 |b 1 |u dzne |
| 700 | 1 | _ | |a Weiß, Merit |b 2 |
| 700 | 1 | _ | |a Chan, Cheuk S J |b 3 |
| 700 | 1 | _ | |a Hepworth, Graham |b 4 |
| 700 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 5 |e Last author |
| 773 | _ | _ | |a 10.1007/s00415-026-13740-1 |g Vol. 273, no. 3, p. 195 |0 PERI:(DE-600)1421299-7 |n 3 |p 195 |t Journal of neurology |v 273 |y 2026 |x 0367-004X |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285634/files/DZNE-2026-00273.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285634/files/DZNE-2026-00273.pdf?subformat=pdfa |x pdfa |y Restricted |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 1 |6 P:(DE-2719)9001369 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811275 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-10 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-10 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2022 |d 2024-12-10 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|